跳转至内容
Merck
CN

Y0000354

阿卡波糖

European Pharmacopoeia (EP) Reference Standard

登录查看公司和协议定价

别名:
阿卡波糖, 4",6"-二脱氧-4"-([1S]-[1,4,6/5]-4,5,6-三羟基-3-羟甲基-2-环己烯基氨基)-麦芽三糖
经验公式(希尔记法):
C25H43NO18
CAS号:
分子量:
645.60
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

acarbose

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

格式

neat

储存温度

2-8°C

SMILES字符串

C[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@@H]2CO)O[C@H]3[C@H](O)[C@@H](O)[C@H](O)O[C@@H]3CO)[C@H](O)[C@@H](O)[C@@H]1N[C@H]4C=C(CO)[C@@H](O)[C@H](O)[C@H]4O

InChI

1S/C25H43NO18/c1-6-11(26-8-2-7(3-27)12(30)15(33)13(8)31)14(32)19(37)24(40-6)43-22-10(5-29)42-25(20(38)17(22)35)44-21-9(4-28)41-23(39)18(36)16(21)34/h2,6,8-39H,3-5H2,1H3/t6-,8+,9-,10-,11-,12-,13+,14+,15+,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-/m1/s1

InChI key

XUFXOAAUWZOOIT-SXARVLRPSA-N

基因信息

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Acarbose for identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

作为可逆性α-葡萄糖苷酶抑制剂的改性四糖。

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

WGK

WGK 1

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Peter N Båvenholm et al.
Diabetes & vascular disease research, 3(2), 72-79 (2006-10-25)
Traditional risk factors do not fully explain the increased risk of cardiovascular disease (CVD) in diabetes. Epidemiology shows that hyperglycaemia is a continuous CVD risk factor and that two-hour postprandial glucose levels are more strongly associated with CVD than fasting
L Furio et al.
Minerva gastroenterologica e dietologica, 52(3), 339-346 (2006-09-15)
The authors report a case report of rare disease interesting the digestive tract and often associated to the other gastrointestinal pathologies and/or pulmonary diseases and can be also associated to not gastrointestinal conditions such as collagen-vascular disease, transplantation, AIDS, use
J de la Vega et al.
Gastroenterologia y hepatologia, 23(6), 282-284 (2004-08-25)
A 57-year-old woman with non-insulin-dependent diabetes mellitus and inadequate glycemic control was prescribed acarbose (100 mg 3 times daily). Two months later she presented with acute hepatitis (ALT 2,300 IU/l). Other causes of liver damage were excluded. Three months after
[The Study TO Prevent Non-Insulin Dependent Diabetes Mellitus trial (acarbose)].
Rimei Nishimura
Nihon rinsho. Japanese journal of clinical medicine, 63 Suppl 2, 478-482 (2005-03-23)
Sophie Delorme et al.
Current opinion in pharmacology, 5(2), 184-189 (2005-03-23)
The prevalence of glucose intolerance is increasing dramatically worldwide. Both impaired glucose tolerance (IGT) and type 2 diabetes are associated with excess mortality from cardiovascular disease. It is now generally accepted that these cardiovascular complications are related to prevailing hyperglycemia

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门